Kensuke Usuki

Mizonokuchi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study.

Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study.

Journal: Blood research

Published: April 11, 2026

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Journal: Blood cancer journal

Published: February 14, 2026

Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials.

Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials.

Journal: British journal of haematology

Published: December 05, 2025

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

Journal: NEJM evidence

Published: August 26, 2025

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

Journal: British journal of haematology

Published: August 04, 2025

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study.

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study.

Journal: British journal of haematology

Published: April 18, 2025

Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey.

Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey.

Journal: Annals of hematology

Published: March 26, 2025

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia.

Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia.

Journal: EJHaem

Published: January 19, 2025

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.

Journal: International journal of hematology

Published: December 16, 2024

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms.

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms.

Journal: British journal of haematology

Published: December 09, 2024

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Journal: Annals of hematology

Published: November 12, 2024

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.

Journal: British journal of haematology

Published: November 05, 2024

Showing 1-12 of 189

Last Updated: 09/26/2026